Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Objective: With the advent of the anaplastic lymphoma kinase (ALK) inhibitor, treatment of ALK-positive advanced non-small-cell lung cancer (NSCLC) patients has become more effective while drug costs are still a major concern. This...
Saved in:
Main Authors: | Sumitra Thongprasert, Unchalee Permsuwan |
---|---|
Format: | Journal |
Published: |
2018
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85015768144&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/47170 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Sumitra Thongprasert, et al.
Published: (2018) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Thongprasert S., et al.
Published: (2017) -
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert,S., et al.
Published: (2015) -
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert S., et al.
Published: (2014) -
Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
by: Unchalee Permsuwan, et al.
Published: (2020)